# Predictors of Prosthetic Valve Endocarditis following Transcatheter Aortic Valve Replacement: A Meta-Analysis

Weiwei Jiang, MD, PhD,<sup>1\*</sup> Wenconghui Wu, MS,<sup>2\*</sup> Ruikang Guo, MS,<sup>3</sup> Minghui Xie, MS,<sup>3</sup> Wai Yen Yim, MS,<sup>3</sup> Yin Wang, MD, PhD,<sup>3</sup> Xingjian Hu, MD, PhD<sup>3</sup>

<sup>1</sup>Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; <sup>2</sup>Department of Gastroenterology, Zhongnan Hospital, Wuhan University, Wuhan, China; <sup>3</sup>Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

# ABSTRACT

**Background:** Transcatheter aortic valve replacement (TAVR) has gained increasing acceptance for patients with aortic disease. A rare but fatal complication prosthetic valve endocarditis (PVE) could greatly influence the clinical outcomes of TAVR. This meta-analysis aims to pin down the predictors of PVE in TAVR patients.

**Methods:** We performed a systematic search for studies that reported the incidence and risk factors of PVE after TAVR. Data on studies, patients, baseline characteristics, and procedural characteristics were abstracted. Crude risk ratios (RRs) and 95% confidence intervals for each predictor were calculated by the use of random-effects models. Heterogeneity assumption was assessed by an I<sup>2</sup> test.

**Results:** We obtained data from 8 studies that included 68,805 TAVR patients, of whom 1,256 (1.83%) were diagnosed with PVE after TAVR. 280 patients died within the 30-days of PVE diagnosis and the pooled in-hospital mortality was 22.3%. The summary estimates indicated an increased risk of PVE after TAVR for males (RR 1.53, P = .0001); for patients with orotracheal intubation (RR 1.65, P = .01), new pacemaker implantation (RR 1.46, P = .003), and residual aortic regurgitation ( $\geq 2$  grade) (RR 1.62, P = .05); while older age (RR 0.74, P = .02) were associated with a lower risk of PVE after TAVR.

Received November 9, 2020; accepted December 1, 2020.

This study was financially supported by the National Natural Science Foundation of China (NO.81700317) to Y.W. and (NO. 81400290) to X.H.


Correspondence: Yin Wang, MD, PhD, Department of Cardiovascular Surgery, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, #1277 Jiefang Avenue, 430022, Wuhan, China; +8613628642979 (e-mail: 2013xh0859@bust.edu.cn).

Xingjian Hu, MD, PhD, Department of Cardiovascular Surgery, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, #1277 Jiefang Avenue, 430022, Wuhan, China; +8615827346676 (e-mail: peterbu9517@bust.edu.cn). **Conclusion:** Clinical characteristics and periprocedure factors including age, male sex, valve type, orotracheal intubation, pacemaker implantation, and residual regurgitation were proven to be associated with the occurrence of PVE-TAVR. Clinicians should pay particular attention to PVE when treating TAVR patients with these predictors.

# INTRODUCTION

Prosthetic valve endocarditis after transcatheter aortic valve replacement (TAVR-PVE) is a relatively rare but fatal complication. The most common pathogens causing TAVR-PVE includ Enterococci, Staphylococcus aureus, and coagulase-negative staphylococci. While some literature suggests the incidence appears to be as low as 0.3% to 1.2% per person-year [Misawa 2015; Kolte 2018], the absolute number of cases is likely to rise substantially as TAVR expands into mid and low-risk populations following the publication of the PARTNER 3 and Evolut Low Risk trials [Mack 2019; Braghiroli 2020; Popma 2019]. Treatment of TAVR-PVE largely parallels that of conventional prosthetic valve endocarditis, with prolonged intravenous antibiotic therapy and consideration of surgical intervention forming the cornerstones of management. However, the effect of treatment with surgery or antibiotics is poor, with high mortality rates (in-hospital mortality is 15% to 30%) secondary to heart failure and acute kidney injury [Bax 2019; Tan 2015]. Besides, the early diagnosis of TAVR-PVE is still challenging, given that the presentation is often asymptomatic and the echocardiographic findings are diverse, while robust evidence for specific preventative strategies of this complication is lacking. All these highlight the need for identifying reliable predictors of TAVR-PVE for surgeons or physicians to targeted follow-up and timely intervention. A few researchers focused on this problem and their registry studies based on different populations came to different or even conflicting conclusions. Therefore, we systematically reviewed all studies regarding this topic and employed a meta-analytic strategy to analyze these data with a twofold aim: (i) to determine pooled, final incidence and mortality of PVE in this specific TAVR population, and (ii) to identify perioperative parameters that best discriminated between TAVR patients with and without PVE.

<sup>\*</sup>These authors contributed equally to the work.



Aae

Figure 1. Study selection flow diagram.

# MATERIALS AND METHODS

## Search Strategy

We performed a broad, computerized literature search of certain text and keywords in Medline, EMBASE, and the CENTRAL trials registry of the Cochrane Collaboration through February 2020. The keywords included 'Transcatheter aortic valve implantation', 'Transcatheter aortic valve replacement', 'TAVI', 'TAVR', 'Endocarditis', 'Infective endocarditis', 'Prosthetic valve endocarditis', 'Infective endocarditis', 'Prosthetic valve endocarditis', 'Infective endocarditis', 'Prosthetic valve endocarditis after TAVI', 'Incidence and clinical impact of infective endocarditis on TAVI', 'TAVI-associated infective endocarditis', 'Prosthetic valve endocarditis after transcatheter valve replacement', 'Causative organisms of post-TAVI infective endocarditis', 'Clinical outcomes of infective endocarditis after TAVI', 'In-hospital mortality', 'Mortality at follow-up', 'Transcatheter heart failure', and 'Outcomes of TAVI.'

# Inclusion and Exclusion Criteria

The inclusion criteria were as follows: (a) studies illustrating the incidence and risk factors of PVE after TAVR, reporting odds ratios (ORs), risk ratios (RRs) or hazard ratios (HRs), and (b) cohort studies including patients with PVE and patients without PVE. Studies were excluded for the following reasons: (a) the studies were abstracts, editorials, letters, reviews, comments, or case reports, (b) the sample size was less than 20, (c) the studies utilized duplicate databases, or (d) the studies did not include human subjects. If ORs were reported by univariate and multivariate analysis simultaneously, only multivariate ORs were included. Two investigators independently conducted the literature searches, the study eligibility assessment, and the data extraction in duplicate. Any discrepancies were resolved by consensus and arbitration by a third investigator.

# Data Extraction and Quality Assessment

The following study- and patient-related information was extracted from the main paper and any accompanying

Butt 201	2019	-0.0202 0.0				
Fauchier	9	0.01 0.0 -0.0222 0.0	154 16.6 042 22.9	% 1.01 [0.9 % 0.98 [0.9	8, 1.04]	1
Kolte 20			042 22.9			1
Regueiro		-0.0305 0.	016 16.2	% 0.97 [0.9		-
Tabata 2	020	-0.1054 0.0	292 9.3	% 0.90 [0.8	5, 0.95]	-
Total (9	5% CI)		100.0	% 0.97 [0.9	5.0.991	
Heteroge	eneity: Tau <sup>2</sup> =	0.00; Chi <sup>2</sup> = 25.07, d			%	0.2 0.5 1 2 5
Test for	overall effect: 3	Z = 2.71 (P = 0.007)				0.2 0.5 1 2 5 Lower risk of IE Higher risk of IE
						Lond for the register for of the
ale				Risk Ratio		Risk Ratio
				Random, 95% C		IV, Random, 95% Cl
Amat-Sar Bjursten 2	ntos 2015	-0.1165 0.3711 0.4318 0.2003	6.7% 14.5%	0.89 [0.43, 1.84		
Butt 2019		0.7129 0.2106	13.8%	2.04 [1.35, 3.08		
Fauchier		0.5749 0.0671	25.2%	1.78 [1.56, 2.0]	3]	-
Kolte 201 Olsen 201	.8 15	0.174 0.1369 2.5039 1.0251	19.5% 1.1% 1	1.19 [0.91, 1.56	2] 2]	
Regueiro		0.4947 0.1946	14.9%	1.64 [1.12, 2.40		
Tabata 20	020	-0.1393 0.4946	4.2%	0.87 [0.33, 2.29	9]	
Total (95	% CI)		100.0%	1.53 [1.24, 1.90	01	•
Heteroger	neity: Tau <sup>2</sup> = 0.0	04; Chi <sup>2</sup> = 16.28, df =	7 (P = 0.02);	$1^2 = 57\%$	0.1	0.2 0.5 1 2 5 10
Test for a	werall effect: Z =	= 3.88 (P = 0.0001)			0.1	Lower risk of TAVI-IE Higher risk of TAVI-IE
abetes						
		log[Risk Ratio]	SF Waint	Risk Rat t IV, Random,		Risk Ratio IV, Random, 95% Cl
	intos 2015	0.0198 0.4				
Bjursten	2019	0.2624 0.2	228 14.0	% 1.30 [0.8		<b>+-</b>
Butt 201		-0.0834 0.2			6, 1.51]	
Fauchier Kolte 20		-0.1416 0.0 -0.1815 0.1			5, 1.00]	
Olsen 20			556 3.7			
Regueiro		0.4447 0.1				
Tabata 2	020	0.8286 0.	488 4.6			
Total (9	FAX (CI)					
					6 1 2 5 1	
		0.04: Chi <sup>2</sup> - 14.05	100.0 df = 7 (P = 0		6, 1.35]	► <b>•</b>
Heteroge	eneity: Tau <sup>2</sup> =	0.04; Chi <sup>2</sup> = 14.05, o Z = 0.66 (P = 0.51)			6, 1.35]	
Heteroge	eneity: Tau <sup>2</sup> =	0.04; Chi <sup>2</sup> = 14.05, d Z = 0.66 (P = 0.51)			6, 1.35]	0.1 0.2 0.5 i 2 5 10 Lower risk of IE Higher risk of IE
Heteroge	eneity: Tau <sup>2</sup> =				6, 1.35]	
Heteroge Test for	eneity: Tau <sup>2</sup> =				.,,	
Heteroge Test for	eneity: Tau <sup>2</sup> = overall effect: .	Z = 0.66 (P = 0.51)	df = 7 (P = 0 SE Weig	0.05); I <sup>2</sup> = 50% Risk Ra ht IV, Random	tio	Lower risk of IE Higher risk of IE
Heteroge Test for OPD <u>Study o</u> Amat-Si	eneity: Tau <sup>2</sup> = overall effect: : or <b>Subgroup</b> antos 2015	Z = 0.66 (P = 0.51)	df = 7 (P = 0 <u>SE Weig</u> 4056 6.0	Risk Ra ht IV, Random	tio , 95% CI 56, 2.75]	Lower risk of IE Higher risk of IE Risk Ratio
Heteroge Test for OPD <u>Study o</u> Amat-Si Bjursten	eneity: Tau <sup>2</sup> = overall effect: ; or Subgroup antos 2015 a 2019	Z = 0.66 (P = 0.51) log[Risk Ratio] 0.2151 0.4 0.0862 0.3	df = 7 (P = 0 <u>SE Weig</u> 4056 6.0 2407 12.3	Risk Ra ht IV, Random % 1.24 [0.5]	tio , 95% CI 56, 2.75] 58, 1.75]	Lower risk of IE Higher risk of IE Risk Ratio
Heteroge Test for OPD <u>Study o</u> Amat-S: Bjursten Butt 203	eneity: Tau <sup>2</sup> = overall effect: : or <b>Subgroup</b> antos 2015 1 2019 19	Z = 0.66 (P = 0.51) log[Risk Ratio] 0.2151 0. 0.0862 0.3 -0.3567 0.3	df = 7 (P = 0 <u>SE Weig</u> 4056 6.0 2407 12.3 2855 10.3	Risk Ra t IV, Random 1.24 [0.1 3% 1.09 [0.6 3% 0.70 [0.4	tio , 95% CI 56, 2.75] 58, 1.75] 40, 1.22]	Lower risk of IE Higher risk of IE Risk Ratio
Heteroge Test for OPD <u>Study o</u> Amat-Si Bjursten	eneity: Tau <sup>2</sup> = overall effect: : overall effec	Z = 0.66 (P = 0.51)	SE         Weig           4056         6.0           2407         12.1           2855         10.3           0705         28.5	Risk Ra           ht         IV, Random           0%         1.24 [0.1]           10%         1.09 [0.6]           0%         0.70 [0.4]           0%         0.86 [0.7]	tio , 95% CI 56, 2.75] 58, 1.75] 40, 1.22] 75, 0.99]	Lower risk of IE Higher risk of IE Risk Ratio
Heteroge Test for OPD <u>Study o</u> Amat-Sc Bjursten Butt 20: Fauchiei Kolte 2C Olsen 2'	nelity: Tau <sup>2</sup> = overall effect: : <u>r Subgroup</u> antos 2015 o 2019 19 r 2020 D18 015	Z = 0.66 (P = 0.51) log[Risk Ratio] 0.2151 0.4 0.0862 0.1 -0.1508 0.6 0.0257 0.1 -1.0498 0.5	SE         Weig           4056         6.0           2407         12.3           2855         10.3           0705         28.9           1399         21.1           9928         1.2	Risk Ra <b>Risk Ra</b> <b>IV, Random</b> 1.24 [0.1 3% 1.09 [0.4 3% 0.70 [0 3% 0.86 [0.1 3% 1.03 [0.1 3% 1.03 [0.1	tio , 95% CI 56, 2.75] 58, 1.75] 40, 1.22] 75, 0.99] 78, 1.35] 05, 2.45]	Lower risk of IE Higher risk of IE Risk Ratio
Heteroge Test for OPD <u>Study o</u> Amat-Si Bjursten Butt 201 Fauchie Kolte 202 Olsen 2 Reguein	r Subgroup antos 2015 2019 19 r 2020 2018 015 o 2016	Z = 0.66 (P = 0.51) log[Risk Ratio] 0.2151 0. 0.0862 0. -0.1567 0. -0.1568 0. 0.0257 0. -1.0498 0.5 0.5068 0.	SE         Weig           4056         6.0           2407         12.1           2855         10.3           0705         28.9           1399         21.1           9928         1.3           1962         16.3	Risk Ra Risk Ra t IV, Random 0, 1, 24 [0.] 1, 24 [0.] 1, 24 [0.] 1, 24 [0.] 1, 0.9 [0.4 1, 0.7 [0.4] 1, 0.3 [0.7 1, 0.3 [0.7] 1, 0.3 [0.7] 1, 0.3 [0.6] 1, 0.5 [0.5	tio , 95% Cl 56, 2.75] 58, 1.75] 40, 1.22] 75, 0.99] 75, 0.99] 75, 2.45] 13, 2.44]	Lower risk of IE Higher risk of IE Risk Ratio
Heteroge Test for OPD <u>Study o</u> Amat-S: Bjursten Butt 20: Fauchiei Kolte 20: Olsen 2:	r Subgroup antos 2015 2019 19 r 2020 2018 015 o 2016	Z = 0.66 (P = 0.51) log[Risk Ratio] 0.2151 0.4 0.0862 0.1 -0.1508 0.6 0.0257 0.1 -1.0498 0.5	SE         Weig           4056         6.0           2407         12.1           2855         10.3           0705         28.9           1399         21.1           9928         1.3           1962         16.3	Risk Ra Risk Ra t IV, Random 0, 1, 24 [0.] 1, 24 [0.] 1, 24 [0.] 1, 24 [0.] 1, 0.9 [0.4 1, 0.7 [0.4] 1, 0.3 [0.7 1, 0.3 [0.7] 1, 0.3 [0.7] 1, 0.3 [0.6] 1, 0.5 [0.5	tio , 95% Cl 56, 2.75] 58, 1.75] 40, 1.22] 75, 0.99] 75, 0.99] 75, 2.45] 13, 2.44]	Lower risk of IE Higher risk of IE Risk Ratio
Heteroge Test for OPD <u>Study o</u> Amat-S. Bjursten Butt 20) Fauchie Kolte 20 Olsen 21 Reguein Tabata 3 Total (9	r Subgroup antos 2015 1 2019 19 17 2020 018 015 0 2016 2020 95% CI)	Z = 0.66 (P = 0.51) log[Risk Ratio] 0.2151 0. 0.0367 0. -0.3567 0. -0.3567 0. -0.1508 0. 0.0257 0. -1.0498 0. 0.2852 0.5	SE         Weig           4056         6.6           2407         12.1           2855         10.0           0705         28.1           3992         21.3           19928         1.4           1962         16.3           5761         3.3           1000.0	Risk Ra           ht         IV, Random           %         1.24 [0.9]           %         1.24 [0.9]           %         0.70 [0.4]           %         0.70 [0.4]           %         0.35 [0.4]           %         1.03 [0.4]           %         1.03 [0.4]           %         1.03 [0.4]	tio <u>, 95% Cl</u> 56, 2.75] 58, 1.75] 40, 1.22] 75, 0.99] 78, 1.35] 55, 2.45] 13, 2.44] 43, 4.11]	Lower risk of IE Higher risk of IE Risk Ratio
Heterogy Test for OPD <u>Study o</u> Amat-S: Bjursten Butt 20: Fauchie Kolte 2C Olsen 2: Reguein Tabata i Total (9 Heterog	eneity: Tau <sup>2</sup> = overall effect: : antos 2015 2019 19 r 2020 015 o 2016 2020 05% CI) eneity: Tau <sup>2</sup> =	Z = 0.66 (P = 0.51) log[Risk Ratio] 0.2151 0 0.03567 0. -0.1508 0. 0.0257 0. -0.1508 0. 0.0568 0. 0.2852 0. 0.0498 0. 0.0488 0. 0.04	SE         Weig           4056         6.6           2407         12.1           2855         10.0           0705         28.1           3992         21.3           19928         1.4           1962         16.3           5761         3.3           1000.0	Risk Ra           ht         IV, Random           %         1.24 [0.9]           %         1.24 [0.9]           %         0.70 [0.4]           %         0.70 [0.4]           %         0.35 [0.4]           %         1.03 [0.4]           %         1.03 [0.4]           %         1.03 [0.4]	tio <u>, 95% Cl</u> 56, 2.75] 58, 1.75] 40, 1.22] 75, 0.99] 78, 1.35] 55, 2.45] 13, 2.44] 43, 4.11]	Lower risk of IE Risk Ratio IV, Random, 95% CI 
Heterogy Test for DPD <u>Study o</u> Amat-S: Bjursten Butt 20: Fauchie Kolte 2C Olsen 2: Reguein Tabata i Total (9 Heterog	eneity: Tau <sup>2</sup> = overall effect: : antos 2015 2019 19 r 2020 015 o 2016 2020 05% CI) eneity: Tau <sup>2</sup> =	Z = 0.66 (P = 0.51) log[Risk Ratio] 0.2151 0. 0.0367 0. -0.3567 0. -0.3567 0. -0.1508 0. 0.0257 0. -1.0498 0. 0.2852 0.5	SE         Weig           4056         6.6           2407         12.1           2855         10.0           0705         28.1           3992         21.3           19928         1.4           1962         16.3           5761         3.3           1000.0	Risk Ra           ht         IV, Random           %         1.24 [0.9]           %         1.24 [0.9]           %         0.70 [0.4]           %         0.70 [0.4]           %         0.35 [0.4]           %         1.03 [0.4]           %         1.03 [0.4]           %         1.03 [0.4]	tio <u>, 95% Cl</u> 56, 2.75] 58, 1.75] 40, 1.22] 75, 0.99] 78, 1.35] 55, 2.45] 13, 2.44] 43, 4.11]	Lower risk of IE Risk Ratio IV, Random, 95% CI
Heterogy Test for OPD <u>Study o</u> Amat-S: Bjursten Butt 20: Fauchie Kolte 2C Olsen 2: Reguein Tabata i Total (9 Heterog	eneity: Tau <sup>2</sup> = overall effect: : antos 2015 2019 19 r 2020 015 o 2016 2020 05% CI) eneity: Tau <sup>2</sup> =	Z = 0.66 (P = 0.51) log[Risk Ratio] 0.2151 0 0.03567 0. -0.1508 0. 0.0257 0. -0.1508 0. 0.0568 0. 0.2852 0. 0.0498 0. 0.0488 0. 0.04	SE         Weig           4056         6.6           2407         12.1           2855         10.0           0705         28.1           3992         21.3           19928         1.4           1962         16.3           5761         3.3           1000.0	Risk Ra           ht         IV, Random           %         1.24 [0.9]           %         1.24 [0.9]           %         0.70 [0.4]           %         0.70 [0.4]           %         0.35 [0.4]           %         1.03 [0.4]           %         1.03 [0.4]           %         1.03 [0.4]	tio <u>, 95% Cl</u> 56, 2.75] 58, 1.75] 40, 1.22] 75, 0.99] 78, 1.35] 55, 2.45] 13, 2.44] 43, 4.11]	Lower risk of IE Risk Ratio IV, Random, 95% CI 
Heterogy Test for OPD Amat-S. Bjursten Butt 201 Fauchie Kolte 22 Olsen 2: Reguein Tabata 1 Total (9 Heterog Test for	eneity: Tau <sup>2</sup> = overall effect: : <b>s Subgroup</b> antos 2015 12019 19 19 10 10 10 2020 05 2020 05 2020 05 2020 05 2020 05 2020 05 2020 05 2020 05 2020 015 015 015 015 015 015 015 01	Z = 0.66 (P = 0.51) log[Risk Ratio] 0.2151 0 0.03567 0. -0.1508 0. 0.0257 0. -0.1508 0. 0.0568 0. 0.2852 0. 0.0498 0. 0.0488 0. 0.04	SE         Weig           4056         6.6           2407         12.1           2855         10.0           0705         28.1           3992         21.3           19928         1.4           1962         16.3           5761         3.3           1000.0	Risk Ra           ht         IV, Random           %         1.24 [0.9]           %         1.24 [0.9]           %         0.70 [0.4]           %         0.70 [0.4]           %         0.35 [0.4]           %         1.03 [0.4]           %         1.03 [0.4]           %         1.03 [0.4]	tio <u>, 95% Cl</u> 56, 2.75] 58, 1.75] 40, 1.22] 75, 0.99] 78, 1.35] 55, 2.45] 13, 2.44] 43, 4.11]	Lower risk of IE Risk Ratio IV, Random, 95% CI 
Heterogy Test for OPD Study o Amat-S: Bjursten Butt 201 Fauchie Kolte 20 Olsen 2 Reguein Tabata 1 Total (5 Heterog Test for	r Subgroup antos 2015 2019 12019 12019 12020 12019 12020 1200 1200 1200 1200 1	log[Risk Ratio]           0.2151         0.           0.2151         0.           0.0367         0.           0.0367         0.           0.0357         0.           0.0457         0.           0.0568         0.           0.2557         0.           0.5068         0.           0.2652         0.           0.044         Chi <sup>2</sup> = 13.64,           z = 0.25 (P = 0.80)         Sufficiency	SE         Weig           4056         6.           4056         6.           4207         12.           2855         10.           7070         28.           1399         21.           9928         1.           1962         16.           5761         3.           100.         df = 7 (P =	No.5);         I <sup>2</sup> = 50%           Risk Ra         Random           ht         V/, Random           %         1.24 (0.5)           %         1.24 (0.5)           %         0.70 (0.6)           %         1.03 (0.6)           %         1.33 (0.4)           %         1.33 (0.4)           %         1.33 (0.4)           %         1.33 (0.4)           %         1.33 (0.4)           %         1.33 (0.4)           %         1.33 (0.4)           %         Risk Ra	tio , 95% Cl 36, 2.75] 38, 1.75] 40, 1.22] 75, 0.99] 78, 1.35] 13, 2.45] 13, 2.44] 43, 4.11] 33, 1.28] tio	Lower risk of IE Risk Ratio IV, Random, 95% CI IV, Random, 95%
Heterogy Test for	reity: Tau <sup>2</sup> = overall effect: : antos 2015 (2019 (2020)	Z = 0.66 (P = 0.51) log[Risk Ratio] 0.2151 0. 0.0682 0. 0.03567 0. 0.03567 0. 0.0257 0. 0.045 Ch <sup>2</sup> = 13.64, Z = 0.25 (P = 0.80) Sufficiency log[Risk Ratio]	SE         Weig           0056         6.6           4077         12.1           2855         10.0           719928         1.3           1399         21.           9528         1.3           9621         1.3           100.0         df = 7 (P =           SE         Weig           SE         Weig	Risk Ra t IV, Random 1.24 [0] 1.24 [0] 1.24 [0] 1.24 [0] 1.24 [0] 1.24 [0] 1.03 [0] 1.03 [0] 1.03 [0] 1.33 [0] 1.3	tio , 95% CI 56, 2.75 58, 1.75 10, 1.22 75, 1.35 15, 2.45 13, 2.44 13, 4.11 33, 1.28 33, 1.28 tio , 95% CI	Lower risk of IE Risk Ratio IV, Random, 95% CI IV, Random, 95% CI I, Risk Ratio IV,
Heterogy Test for OPD <u>Study o</u> Amat-S: Bjursten Butt 201 Fauchie Kolte 20 Olsen 2: Reguein Tabata : Total (9 Heterog Test for	r Subgroup antos 2015 2020 1015 2020 1018 2020 2020	Z = 0.66 (P = 0.51) log[Risk Ratio] 0.2151 0.0 0.3657 0.0 -0.3567 0.0 -0.3567 0.0 -0.3567 0.0 -0.3570 0.0 0.0257 0.0 0.0457 0.0 0.2552 0.1 0.2552 0.1 0.2552 (P = 0.80) Sufficiency log[Risk Ratio] -0.3711 0.1	SE         Weig           056         6.0           4407         12.1           12855         10.3           10705         28.4           1399         21.4           1962         16.5           5761         3.3           100.c         df = 7 (P =           SE         Weig           3763         4.0	Risk Ra           ht IV. Random           %           1.24 [0.1%]           %           1.24 [0.1%]           %           1.24 [0.1%]           %           1.09 [0.1%]           %           1.03 [0.1%]           %           0.35 [0.1%]           0.35 [0.1%]           0.36 [0.1%]           1.33 [0.1%]           %           1.33 [0.1%]           %           1.33 [0.1%]           %           1.33 [0.1%]           %           1.33 [0.1%]           %           1.33 [0.1%]           %           1.33 [0.1%]           %           1.33 [0.1%]           %           1.33 [0.1%]           %           1.33 [0.1%]           %           1.33 [0.1%]           %           1.33 [0.1%]           %           1.33 [0.1%]           %           %           %           %           %           %           %	tio <u>, 95% Cl</u> 56, 2.75] 58, 1.75] 40, 1.22] 75, 0.99] 75, 0.99] 75, 0.99] 75, 0.99] 75, 0.99] 75, 0.99] 75, 0.99] 75, 0.99] 13, 2.44] 33, 1.28] tio <u>, 95% Cl</u>	Lower risk of IE Risk Ratio IV, Random, 95% CI IV, Random, 95%
Heterogy Test for OPD <u>Study o</u> Amat-S. Bjursten But 20: Fauchie Kolte 20 Olsen 2: Reguein Tabata : Total (S Heterog Test for	reity: Tau <sup>2</sup> = overall effect: : r Subgroup antos 2015 (2019 12 2020 12 2020 12 2020 12 2020 12 2020 12 2020 12 2020 reenal in: r Subgroup antos 2015 2019	Z = 0.66 (P = 0.51) log[Risk Ratio] 0.2151 0. 0.0682 0. 0.03567 0. 0.03567 0. 0.0257 0. 0.045 Ch <sup>2</sup> = 13.64, Z = 0.25 (P = 0.80) Sufficiency log[Risk Ratio]	SE         Weig           4056         6.6           4056         6.6           2407         12.1           3992         21.1           3992         12.1           1962         16.7           1962         16.7           1962         16.7           100.0         df = 7 (P =           SE         Weig           3763         4.4           1685         12.4	Risk Ra           NU V, Random           Misk Ra           NU V, Random           Misk Ra           NU V, Random           Misk Ra           NU N, Random           Misk Ra           Nu N, Random           Misk Ra           Nu N, Song	tio , 95% CI 86, 2.75] 58, 1.75] 58, 1.75] 58, 1.75] 58, 1.75] 58, 1.75] 58, 1.75] 58, 1.75] 58, 1.75] 51, 2.45] 52, 2.4	Lower risk of IE Risk Ratio IV, Random, 95% CI IV, Random, 95%
Heterogr Test for DPD Study o Amat-S. Bjursten Butt 20 Fauchie Kolte 22 Olsen 2 Reguein Tabata i Total (9 Heterog Test for DrONIC	rneity: Tau <sup>2</sup> = overall effect: : antos 2015 2019 19 2020 118 0 2016 2020 2020 2020 2020 2020 2020 2020	Z = 0.66 (P = 0.51) log[Risk Ratio] 0.2151 0. 0.0862 0. 0.0862 0. 0.0257 0. 0.0257 0. 0.0258 0. 0.0258 0. 0.0285 0. 0.045 Chi <sup>2</sup> = 13.64, Z = 0.25 (P = 0.80) sufficiency log[Risk Ratio] -0.3711 0. -0.4743 0. 0.7324 0. -0.7324 0. -0.7344 0. -0.7344 0. -0.7344 0. -0.7454 0.	SE         Weig           4056         6.6           4056         6.6           2407         12.2           255         10.0           1399         21.1           3928         1.2           1399         21.6           3928         1.6           100.0         df = 7 (P =           SE         Weig           3763         4.4           1685         12.2           2477         7.7           3804         21.1	Risk Ra           Nt IV, Random           %         1.24 (0.%           %         1.24 (0.%           %         1.24 (0.%           %         0.35 (0.%           %         0.35 (0.%           %         0.35 (0.%           %         0.35 (0.%           %         0.35 (0.%           %         0.36 (0.%           %         1.33 (0.%           %         0.36 (0.%           %         0.64 (0.%)           %         0.64 (0.%)           %         0.64 (0.%)           %         0.64 (0.%)           %         0.64 (0.%)           %         0.64 (0.%)           %         0.62 (0.%)	tio 95% CI 6, 2, 75] 58, 1, 75] 58, 1, 75] 58, 1, 75] 57, 2, 45] 13, 2, 44] 13, 4, 11] 13, 4, 11] 13, 4, 11] 14, 128] tio 95% CI 16, 0, 89] 8, 3, 38, 107]	Lower risk of IE Risk Ratio IV, Random, 95% CI IV, Random, 95%
Heterogy Test for DPD Study o Amat-Si Bjursten Butt 20 Fauchie Kolte 22 Olsen 2: Reguein Tabata : Total (9 Heterogy Test for Dronic Study o Amat-Si Bjursten Butt 20 Fauchie Study o Amat-Si Bjursten Butt 20 Fauchie Study o Amat-Si Bjursten Butt 20 Fauchie Study o	r Subgroup artos 2015 2019 19 10 2020 2020 2020 2020 2020 202	Z = 0.66 (P = 0.51) log[Risk Ratio] 0.2151 0 0.0862 0; -0.1508 0; -0.1508 0; 0.0257 0; 0.0257 0; 0.0452 0; 0.045	SE         Weig           4d = 7 (P = 0           4056         6.0           2407         12.1           255         10.0           3139         21.1           3199         21.1           91062         16.6           5761         3.3           1000.0         df = 7 (P =           SE         Weig           3763         4.4           1685         12.4           2477         7.3           3804         21.1           374         13.7	Risk Ra           ht         IV, Random           5%         1.24 [0].           5%         1.24 [0].           5%         1.09 [0].           5%         1.09 [0].           5%         1.03 [0].           6%         1.33 [0].           5%         1.33 [0].           5%         1.33 [0].           5%         1.33 [0].           5%         0.65 [0].           6%         1.33 [0].           6%         0.63 [0].           6%         0.65 [0].           6         0.65 [0].           6         0.65 [0].           7%         0.65 [0].           6         0.65 [0].           7%         0.64 [0].           7%         0.84 [0].           7%         0.91 [0].	tio <u>95% CI</u> 56, 2.75 58, 1.75 50, 01, 122 75, 0.99 78, 1.35 13, 2.45 13, 2.44 13, 4.11 13, 1.48 13, 1.28 10, 0.89 12, 3.38 14, 11 15, 0.49 15, 0.49	Lower risk of IE Risk Ratio IV, Random, 95% CI IV, Random, 95%
Heterogr Test for OPD Amat-S. Bjursten Butt 20, Fauchie Kolte 22, Oisen 2: Reguein Tabata : Total (9 Heterog Test for Amat-S. Bjursten Butt 20; Fauchie Kolte 22, Oisen 2:	rsubgroup           antos 2015           12019           19           12019           18           02020           195           2020           195           2020           195           2020           195           1015           20200           195           195           190           191           192           192           193           194           195           195           191           192           193           194           195           195           191           191           191           192           193           1015	Z = 0.66 (P = 0.51) log[Risk Ratio] 0.2151 0. 0.0860 0. -0.3576 0. -0.3576 0. -0.0257 0. 0.045 Chi <sup>2</sup> = 13.64, Z = 0.25 (P = 0.80) sufficiency log[Risk Ratio] -0.3711 0. -0.3714 0. -0.3744 0. -0.3744 0. -0.3724 0. -0.3744 0. -0.3744 0. -0.3	SE         Weig           4056         6.           4056         6.           4026         6.           102         2.           3139         21.           3199         21.           3199         21.           3199         21.           3199         21.           3199         21.           3192         1.           3192         1.           3102         1.           3103         4.           1085         1.           2477         7.           3044         1.           3054         1.	Risk Random           N. 10, Kandom           Will 24 (0.0)           Will 124 (0.0)	tio ,95% CI ,95% CI ,95% CI ,25% 0.99 ,25% 0.00 ,25% CI ,33, 1.44] ,128 ,244 ,33, 1.28] tio ,95% CI ,33, 1.44] tio ,95% CI ,33, 1.44] tio ,128 ,244 ,25% 0.00 ,25% 0.0	Lower risk of IE Risk Ratio IV, Random, 95% CI IV, Random, 95%
Heterogy Test for DPD Study o Amat-Si Bjursten Butt 20 Fauchie Kolte 22 Olsen 2: Reguein Tabata : Total (9 Heterogy Test for Dronic Study o Amat-Si Bjursten Butt 20 Fauchie Study o Amat-Si Bjursten Butt 20 Fauchie Study o Amat-Si Bjursten Butt 20 Fauchie Study o	rr Subgroup           antos 2015           2019           12           2020           2035           2020           2035           2020           2055           2020           2055           2020           2055           concall effect:           reenall effect:           r Subgroup           antos 2015           2020           103           203           203           204           205           2015           2020           2030           2040           2031           2032           2033           2034           2035           2035           2036           2036	Z = 0.66 (P = 0.51) log[Risk Ratio] 0.2151 0 0.0862 0; -0.1508 0; -0.1508 0; 0.0257 0; 0.0257 0; 0.0452 0; 0.045	SE         Weig           4056         6.           4056         6.           2407         12.           2855         10.           7075         28.8           1399         21.           1962         16.           5761         3.           1000.         df = 7 (P =           21         100.           df = 7 (P =         24.           3763         4.4           1685         12.           2477         7.           3804         21.           374         15.           41574         2.           1997         10.	Nisk Ra           Nt         IV, Random           Mi         1.24 [0].           Mi         1.24 [0].           Mi         1.09 [0].           Mi         1.03 [0].           Mi         1.03 [0].           Mi         1.03 [0].           Mi         1.33 [0].           Mi         1.38 [0]. <t< td=""><td>tio , 95% C1 66, 2.75] 10, 1.22] 78, 1.35] 75, 2.45] 13, 2.44] 13, 2.44] 13, 2.44] 13, 2.44] 13, 1.48] 16, 1.49] 18, 3.48] 18, 3.43] 10, 2.60] 10, 2.45] 10, 2.4</td><td>Lower risk of IE Risk Ratio IV, Random, 95% CI IV, Random, 95%</td></t<>	tio , 95% C1 66, 2.75] 10, 1.22] 78, 1.35] 75, 2.45] 13, 2.44] 13, 2.44] 13, 2.44] 13, 2.44] 13, 1.48] 16, 1.49] 18, 3.48] 18, 3.43] 10, 2.60] 10, 2.45] 10, 2.4	Lower risk of IE Risk Ratio IV, Random, 95% CI IV, Random, 95%
Heteroge Test for DPD Study of Amat-Se Baut200 Fautchie Kolte 22 Olsen 22 Reguein Tabata 3 Total (6 Heteroge Test for Noncold Study of Amat-Se But 200 Fautchie Kolte 22 Olsen 22 Reguein Tabata 3 Study of Study of Fautchie Kolte 22 Olsen 2 Reguein Tabata 3 Study of Study of S	r Subgroup antos 2015 2019 19 2020 2020 2020 2020 2020 2020 2	$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	SE         Weig           0056         6.           4056         6.           4056         6.           207         12.           2855         10.           705         28.           1399         21.           9928         1.           1962         16.           5761         3.           1000.         df = 7 (P =           SE         Weig           2763         4.           1685         12.           2477         7.           1874         13.           1374         15.           4776         2.           4997         10.           01003         26.	Risk Ra           ht         IV, Random           %         1.24 [0.3]           %         1.24 [0.3]           %         1.24 [0.3]           %         1.09 [0.4]           %         1.09 [0.4]           %         1.03 [0.4]           %         0.35 [0.4]           %         0.35 [0.4]           %         0.35 [0.4]           %         0.35 [0.4]           %         0.36 [0.5]           %         0.64 [0.7]           %         0.69 [0.7]           %         0.69 [0.7]           %         0.91 [0.6]           %         0.91 [0.7]           %         0.91 [0.7]           %         0.91 [0.7]           %         0.91 [0.7]           %         0.91 [0.7]           %         0.91 [0.7]           %         0.71 [0.7]           %         0.70 [0.7]           %         1.00 [0.7]	tio , 95% CI , 95% CI , 95% CI , 95% CI , 3, 1, 35 , 2, 44 , 3, 4, 11 , 128 , 135 , 135 , 2, 45 , 3, 2, 44 , 3, 3, 1, 28 , 3, 3, 1, 45 , 4, 102 , 5, 2, 45 , 6, 2, 5 , 7, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10	Lower risk of IE Risk Ratio IV, Random, 95% CI IV, Random, 95%
Heterogr Test for Study o Amat-Si Bint 300 Bint 300	r Subgroup           antos 2015           3019           7 2020           1018           015           02016           2020           105           02016           2020           105           02016           2020           105           02016           2020           12019           19           12020           12019           19           2020           12016           2020           1205           2020           1205           2020           1205	$\begin{tabular}{l l l l l l l l l l l l l l l l l l l $	SE         Weig           0056         6.6           4056         6.6           2407         12.1           1399         21.1           1962         16.5           5761         3.3           1902         16.5           5761         3.3           1605.         12.2           1763         4.4           1653         1.2           2477         7.7           804         21.1           1374         15.4           4776         2.6           1000.2         100.0	Risk Ra           tt         V, Random           5%         1.24 [0.           1.24 [0.         0.           1.24 [0.         0.           1.24 [0.         0.           1.24 [0.         0.           1.24 [0.         0.           1.25 [0.         0.           1.26 [0.         0.           1.33 [0.         0.           %         1.33 [0.           %         0.35 [0.           %         0.65 [0.           %         0.65 [0.           %         0.91 [0.           %         0.91 [0.           %         1.08 [0.           %         0.91 [0.           %         0.91 [0.           %         0.91 [0.           %         0.91 [0.	tio <u>95% CI</u> 5, 6, 2, 75] 5, 6, 2, 75] 5, 6, 2, 75] 7, 5, 0, 99 7, 1, 35 7, 2, 45] 13, 2, 44] 13, 4, 11] 13, 1, 44] 14, 0, 83 13, 1, 44] 14, 0, 2, 60] 14, 1, 0, 2, 60] 14, 1, 0, 2, 60] 14, 1, 11]	Lower risk of IE Risk Ratio IV, Random, 95% CI 0.1 0.2 0.5 1 2 5 11 Lower risk of IE Risk Ratio IV, Random, 95% CI Risk Ratio IV, Random, 95% CI
Heterogr Test for Study o Study o Sudy o S	rsubgroup           antos 2015           2019           antos 2015           2019           7 3020           18           015           2016           2016           2016           2016           2016           2017           antos 2015           1001           101           101           101           102           103           104           105           105           1019           1019           1019           1019           1019           1019           1019           1010           1011           1012           1013           1014           1015           1015           1016           1015           1015           1015           1016           1017           1018           1019           1010           1010           1010	$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	SE         Weig           0056         6.6           4056         6.6           2407         12.1           1399         21.1           1962         16.5           5761         3.3           1902         16.5           5761         3.3           1605.         12.2           1763         4.4           1653         1.2           2477         7.7           804         21.1           1374         15.4           4776         2.6           1000.2         100.0	Risk Ra           tt         V, Random           5%         1.24 [0.           1.24 [0.         0.           1.24 [0.         0.           1.24 [0.         0.           1.24 [0.         0.           1.24 [0.         0.           1.25 [0.         0.           1.26 [0.         0.           1.33 [0.         0.           %         1.33 [0.           %         0.35 [0.           %         0.65 [0.           %         0.65 [0.           %         0.91 [0.           %         0.91 [0.           %         1.08 [0.           %         0.91 [0.           %         0.91 [0.           %         0.91 [0.           %         0.91 [0.	tio <u>95% CI</u> 5, 6, 2, 75] 5, 6, 2, 75] 5, 6, 2, 75] 7, 5, 0, 99 7, 1, 35 7, 2, 45] 13, 2, 44] 13, 4, 11] 13, 1, 44] 14, 0, 83 13, 1, 44] 14, 0, 2, 60] 14, 1, 0, 2, 60] 14, 1, 0, 2, 60] 14, 1, 11]	Lower risk of IE Risk Ratio IV, Random, 95% CI IV, Random, 95%

Risk Ratio

 Study or Subgroup
 log[Risk Ratio]
 SE
 Weight
 IV, Random, 95% CI

 Amat-Santos 2015
 -0.0202
 0.0213
 13.0%
 0.98 [0.94, 1.02]

Risk Ratio

IV, Random, 95% C

Figure 2. Forest plot of summary crude RRs of each assessed preoperative predictor for patients with prosthetic valve endocarditis after transcatheter aortic valve replacement: age; male sex; diabetes; COPD; chronic renal insufficiency by evaluated IV random-effects model. Heterogeneity estimates (I<sup>2</sup>) are given for those predictors for which datasets from 2 or more studies were available. CI indicates confidence interval; IV, inverse variance.

supplemental material: publication year; study design; study period; follow-up duration; number of participants; number of PVE after TAVR; age; male sex; diabetes; chronic obstructive pulmonary disease; chronic renal insufficiency; LogEuroSCORE (%); mean gradient; valve orifice area; aortic regurgitation (≥moderate); left ventricular ejection fraction; valve embolization; self-expandable valve; transfemoral approach; orotracheal intubation; aortic regurgitation (≥moderate); left ventricular ejection fraction; valve embolization; pacemaker implantation; vascular injury; acute kidney injury; residual aortic regurgitation (≥grade 2); blood transfusion; low implantation, and bleeding complication. The quality of the

#### Aortic regurgitation ≥ moderate

Study or Subgroup	log[Risk Ratio]	SE	Weight	Risk Ratio IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI
Amat-Santos 2015	0	0.4937	2.5%	1.00 [0.38, 2.63]	
Bjursten 2019	0.27	0.1972	15.7%	1.31 [0.89, 1.93]	+
Fauchier 2020	-0.001	0.0866	81.5%	1.00 [0.84, 1.18]	<b>*</b>
Olsen 2015	-0.1744	1.4395	0.3%	0.84 [0.05, 14.11]	· · · · · · · · · · · · · · · · · · ·
Total (95% CI)			100.0%	1.04 [0.89, 1.21]	
Heterogeneity: Tau <sup>2</sup> = Test for overall effect:			(P = 0.64	5); I <sup>2</sup> = 0%	0.1 0.2 0.5 1 2 5 10 Lower risk of IE Higher risk of IE

#### Self-Expandable valve

				Risk Ratio	Risk Ratio	
Study or Subgroup	log[Risk Ratio]	SE	Weight	IV, Random, 95% CI	IV, Random, 95% CI	
Amat-Santos 2015	-0.7971	0.3712	11.7%	0.45 [0.22, 0.93]		
Bjursten 2019	-0.2485	0.1972	41.6%	0.78 [0.53, 1.15]		
Regueiro 2016	-0.1863	0.2008	40.1%	0.83 [0.56, 1.23]		
Tabata 2020	-0.4943	0.4977	6.5%	0.61 [0.23, 1.62]		
Total (95% CI)			100.0%	0.74 [0.58, 0.95]	•	
Heterogeneity: Tau <sup>2</sup>	= 0.00; Chi <sup>2</sup> = 2.3	3, df = 3	(P = 0.5)	1); $I^2 = 0\%$	0.1 0.2 0.5 1 2 5	10
Test for overall effect	: Z = 2.39 (P = 0.0	02)			Lower risk of IE Higher risk of IE	10

#### Orotracheal intubation



#### Transfemoral approach

			Risk Ratio	Risk Ratio
Study or Subgroup	log[Risk Ratio] SE	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Amat-Santos 2015	0.2624 0.4875	3.8%	1.30 [0.50, 3.38]	
Bjursten 2019	-0.3285 0.2513	14.1%	0.72 [0.44, 1.18]	
Butt 2019	-0.2485 0.1783	28.0%	0.78 [0.55, 1.11]	
Kolte 2018	-0.0534 0.1569	36.2%	0.95 [0.70, 1.29]	
Olsen 2015	-0.5621 0.7163	1.7%	0.57 [0.14, 2.32]	
Regueiro 2016	-0.1744 0.235	16.1%	0.84 [0.53, 1.33]	
Total (95% CI)		100.0%	0.85 [0.71, 1.02]	•
Heterogeneity: Tau <sup>2</sup> =	= 0.00; Chi <sup>2</sup> = 2.23, df = 5	(P = 0.8)	2); I <sup>2</sup> = 0%	0.1 0.2 0.5 1 2 5 10
Test for overall effect	Z = 1.73 (P = 0.08)			Lower risk of IE Higher risk of IE

Figure 3. Forest plot of summary crude RRs of each assessed procedural related predictor for patients with prosthetic valve endocarditis after transcatheter aortic valve replacement: aortic regurgitation  $\geq$ moderate, self-expandable valve, orotracheal intubation, transfemoral approach by evaluated IV random-effects model. Heterogeneity estimates (I<sup>2</sup>) are given for those predictors for which datasets from 2 or more studies were available. Cl indicates confidence interval; IV, inverse variance.

included studies was assessed by the Newcastle-Ottawa scale.

## Assessed Predictors of PVE after TAVR

According to a recently published review, we focused on the following previously proposed predictors: age; male sex; diabetes; COPD; chronic renal insufficiency; self-expandable valve; transfemoral approach; orotracheal intubation; aortic regurgitation (≥moderate); pacemaker implantation; vascular injury; residual aortic regurgitation (≥grade 2); and bleeding complication.

## Data Analysis

We pooled RRs using RevMan Software Version 5.3 (The Cochrane Collaboration, London, United Kingdom). The inverse variance method was used to pool multivariate ORs and HRs. Only two or more ORs and HRs were pooled. Heterogeneity across the studies was quantified with the  $I^2$  index: an  $I^2$  of 0-25% renders insignificant heterogeneity; 26-50% low heterogeneity; 51-75% moderate heterogeneity; and >75% high heterogeneity; and a random-effects model was used to obtain the combined effect estimates [Higgins 2002]. Two-sided *P*-values less than .05 were considered statistically significant. Publication bias analysis was performed when pooled studies were more than three. If significant

#### New pacemaker implantation

Study or Subgroup	log[Risk Ratio]	SE	Weight	Risk Ratio IV. Random. 95% CI	Risk Ratio IV. Random, 95% CI
Amat-Santos 2015	-0.1278	0.5323	5.7%	0.88 [0.31, 2.50]	
Biursten 2019	0.571	0.3229	15.4%	1.77 [0.94, 3.33]	
Kolte 2018	0.4447	0.1876	45.5%	1.56 [1.08, 2.25]	
Olsen 2015	0.3577	0.557	5.2%	1.43 [0.48, 4.26]	
Requeiro 2016	0.3221	0.2413	27.5%	1.38 [0.86, 2.21]	+
Tabata 2020	-1.6246	1.4277	0.8%	0.20 [0.01, 3.23]	·
Total (95% CI)			100.0%	1.46 [1.14, 1.87]	•
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 3.41, df = 5 (P = 0.64); I <sup>2</sup> = 0%					01 02 05 1 2 5 10
Test for overall effect	:: Z = 2.98 (P = 0.0	003)			0.1 0.2 0.5 1 2 5 10 Lower risk of IE Higher risk of IE

#### Residual aortic regurgitation

Study or Subgroup	log[Risk Ratio] Si	Weight	Risk Ratio IV, Random, 95% Cl	Risk Ratio IV, Random, 95% CI
Amat-Santos 2015	0.157 0.385	23.6%	1.17 [0.55, 2.49]	
Bjursten 2019	0.0583 0.41	5 21.5%	1.06 [0.47, 2.39]	<b>_</b>
Olsen 2015	1.3762 0.478	5 17.8%	3.96 [1.55, 10.12]	<b>_</b>
Regueiro 2016	0.5128 0.241	5 37.0%	1.67 [1.04, 2.68]	
Total (95% CI)		100.0%	1.62 [1.01, 2.61]	-
Heterogeneity: Tau2 =	= 0.10; Chi <sup>2</sup> = 5.26, df =	3 (P = 0.1)	5); I <sup>2</sup> = 43%	0.1 0.2 0.5 1 2 5 10
Test for overall effect	:: Z = 2.00 (P = 0.05)			Lower risk of IE Higher risk of IE

## Vascular injury

				KISK KALIO			
Study or Subgroup log[Risk Ratio]		sk Ratio] SE		IV, Random, 95% CI	IV, Random, 95% CI		
Amat-Santos 2015	0.2852	0.613	12.5%	1.33 [0.40, 4.42]			
Bjursten 2019	-0.0513	0.702	10.5%	0.95 [0.24, 3.76]			
Kolte 2018	-0.251	0.3231	22.4%	0.78 [0.41, 1.47]			
Olsen 2015	1.1019	0.4608	17.1%	3.01 [1.22, 7.43]			
Regueiro 2016	-0.478	0.3375	21.8%	0.62 [0.32, 1.20]			
Tabata 2020	0.7975	0.502	15.7%	2.22 [0.83, 5.94]			
Total (95% CI)			100.0%	1.20 [0.70, 2.06]			
Heterogeneity: Tau <sup>2</sup> =	= 0.24; Chi <sup>2</sup> = 10.	89, df =	5 (P = 0.0)	05); I <sup>2</sup> = 54%	0.1 0.2 0.5 1 2 5		
Test for overall effect	: Z = 0.66 (P = 0.5	51)			Lower risk of IF Higher risk of IF		

#### Bleeding complications

			Risk Ratio	Risk Ratio
Study or Subgroup	log[Risk Ratio]	E Weight	IV, Random, 95% CI	IV, Random, 95% CI
Kolte 2018	0.4447 0.142	4 44.5%	1.56 [1.18, 2.06]	
Olsen 2015	0.9632 0.461	7 22.5%	2.62 [1.06, 6.48]	
Regueiro 2016	-0.4155 0.353	7 29.0%	0.66 [0.33, 1.32]	
Tabata 2020	0.0583 1.424	3 4.0%	1.06 [0.07, 17.29]	· · · · · · · · · · · · · · · · · · ·
Total (95% CI)		100.0%	1.34 [0.75, 2.40]	-
Heterogeneity: Tau <sup>2</sup> = Test for overall effect	0.18; Chi <sup>2</sup> = 6.91, df = Z = 1.00 (P = 0.32)	3 (P = 0.0	7); I <sup>2</sup> = 57%	0.1 0.2 0.5 1 2 5 10 Lower risk of IE higher risk of IE

Figure 4. Forest plot of summary crude RRs of each assessed postoperative predictor for patients with prosthetic valve endocarditis after transcatheter aortic valve replacement: residual aortic regurgitation  $\geq$ grade 2, vascular injury, bleeding complications by evaluated IV random-effects model. Heterogeneity estimates (I<sup>2</sup>) are given for those predictors for which datasets from 2 or more studies were available. CI indicates confidence interval; IV, inverse variance.

publication bias was noted, Duval and Tweedie's trim and fill method was used to acquire adjusted values. The present systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) group [Liberati 2009].

## RESULTS

The study selection process is presented in Figure 1. A total of 279 citations were retrieved after searching PubMed, EMBASE, and CENTRAL database. There were 106 full-text articles assessed for eligibility after screening titles and abstracts, and we identified 35 studies that reported the incidence of PVE after TAVR. Finally, 8 articles [Kolte 2018; Amat-Santos 2015; Olsen 2015; Bjursten 2019; Fauchier 2020; Tabata 2020; Butt 2019; Regueiro 2016] were ultimately included in the present systematic review and meta-analysis. The main characteristics and the overall quality of the included studies are shown in Table 1. Overall, 68,805 patients were evaluated in 8 studies, and 1,256 (1.83%) were diagnosed with PVE after TAVR. The incidence of PVE after

# Table 1. Characteristics of Included Studies

Leading author	Amat-Santos	Olsen	Ander Regueiro	Henrik Bjursten	Laurent Fauchier	Noriaki Tabata	Dhaval Kolte	Jawad H. Butt
Publication year	2015	2015	2016	2019	2020	2020	2018	2019
Study design	retrospectively	retrospectively	retrospectively	retrospective	retrospectively	prospective	retrospectively	retrospectively
Study period	2007-2014	2007-2014	2005-2015	2008-2018	2010-2018	2008-2018	2013-2014	2008-2016
NOS score	8	7	8	8	8	8	7	8
Number of patients, n	7891	503	6398	4336	16291	1448	29306	2632
Incidence of PVE, n (%)	53 (0.67)	18 (3.58)	250 (1.17)	103 (2.38)	476 (2.92)	17 (1.17)	224 (0.76)	115 (4.37)
In-hospital mortality after PVE, n (%)	25 (47.2)	2 (11.1)	90 (36.0)	8 (15.7)	89 (18.7)	7 (41.2)	35 (15.6)	24(20.9)
Factors	HR (95%CI)	HR (95%CI)	HR (95%CI)	HR (95%CI)	HR (95%CI)	HR (95%CI)	HR (95%CI)	HR (95%CI)
Age, y	0.98 (0.94-1.03)	N/A	0.97 (0.94-0.99)	0.98 (0.96–1.01)	0.98 (0.97-0.99)	0.90 (0.85-0.95)	0.76 (0.66-0.87)	1.01 (0.98-1.04)
Male sex	0.89 (0.43-1.94)	12.23 (1.64-91.2)	1.64( 1.12-2.41)	1.54 (1.04-2.28)	1.78 (1.56-2.03)	0.87 (0.33-2.26)	1.19 (0.91-1.55)	2.04 (1.35-3.07)
Diabetes	1.02 (0.46-2.24)	1.13 (0.38-3.35)	1.56 (1.07-2.78)	1.30 (0.84–1.99)	0.87 (0.76-0.99)	2.29 (0.88-5.97)	0.83 (0.57-1.22)	0.92 (0.56-1.51)
COPD	1.24 (0.56-2.73)	0.35 (0.05-2.6)	1.66 (1.13-2.45)	1.09 (0.68-1.73)	0.86 (0.75-0.99)	1.33 (0.43-4.12)	1.02 (0.78-1.35)	0.70 (0.40-1.21)
eGFR < 60 mL/min	0.69 (0.33-1.43)	1.02 (0.40-2.58)	0.71 (0.48-1.03)	0.64 (0.46-0.88)	0.91 (0.78-1.07)	1.00 (0.98-1.03)	1.08 (0.83-1.42)	2.08 (1.28-3.37)
LogEuroSCORE (%)	1.12 (0.99-1.04)	N/A	N/A	N/A	N/A	0.94 (0.89-1.00)	N/A	N/A
Self-expandable valve	0.45 (0.22-0.93)	N/A	0.83 (0.56-1.22)	0.78 (0.53–1.15)	N/A	0.61 (0.23-1.60)	N/A	N/A
Transfemoral approach	1.30 (0.50-3.41)	0.57 (0.14-2.39)	0.84 (0.53-1.35)	0.72 (0.44-1.17)	N/A	N/A	0.95 (0.69-1.29)	0.78 (0.55-1.21)
Orotracheal intubation	2.56 (1.15-5.68)	N/A	1.55 (1.06-2.27)	1.24 (0.84-1.82)	N/A	N/A	N/A	N/A
Mean gradient (mmHg)	0.99 (0.92-1.06)	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Valve area	1.69 (0.36-2.17)	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Aortic regurgitation (≥moderate)	1.00 (0.38-2.67)	0.84 (0.05-13.3)	N/A	1.31 (0.89–1.94)	0.99 (0.84-1.18)	N/A	N/A	N/A
Left ventricular ejection fraction	1.11 (0.61-2.01)	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Valve embolization	1.72 (0.37-8.09)	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Pacemaker implantation	0.88 (0.31-2.54)	1.43 (0.48-4.22)	1.38 (0.86-2.21)	1.77 (0.94-3.36)	N/A	0.20 (0.01-3.26)	1.56 (1.08-2.26)	N/A
Vascular injury	1.33 (0.40-4.44)	3.01 (1.22-7.43)	0.62 (0.32-1.23)	0.95 (0.24-3.8)	N/A	2.22 (0.83-5.94)	0.78 (0.41-1.46)	N/A
Acute kidney injury	2.05 (0.83-5.08)	N/A	N/A	1.83 (0.27-12.54)	N/A	N/A	0.80 (0.55-1.16)	N/A
Residual aortic regurgitation ≥grade 2	1.17 (0.55-2.46)	3.96 (1.55-10.15)	1.67 (1.04-2.66)	1.06 (0.47-2.4)	N/A	N/A	N/A	N/A
Blood transfusion	N/A	1.46 (0.56-3.81)	N/A	1.98 (0.82-4.75)	N/A	N/A	N/A	N/A
Low implantation	N/A	3.05 (1.20-7.73)	N/A	N/A	N/A	N/A	N/A	N/A
Bleeding complication	N/A	2.62 (1.06-6.49)	0.66 (0.33-1.30)	N/A	N/A	1.06 (0.07-17.3)	1.56 (1.18-2.07)	N/A

Cl indicates confidence interval; COPD, chronic obstructive pulmonary disease; eGFR, estimate glomerular filtration rate; HR, hazard ratio; NOS, Newcastle-Ottawa scale; PVE, prosthetic valve endocarditis.

the intervention ranged from 0.7% to 4.3% in individual studies. The pooled in-hospital mortality was 22.3% (280/1256), ranged from 11.1% to 47.2% in individual studies.

# **Baseline Characteristics-Related Factors**

Older age [Kolte 2018; Amat-Santos 2015; Bjursten 2019; Fauchier 2020; Tabata 2020; Butt 2019; Regueiro 2016] was associated with a lower risk of PVE after TVAR (RR 0.97,

95% CI: 0.95 to 0.99, P = .007), and men sex [Kolte 2018; Amat-Santos 2015; Olsen 2015; Bjursten 2019; Fauchier 2020; Tabata 2020; Butt 2019; Regueiro 2016] was identified as a predictor of PVE after TVAR (RR 1.53, 95% CI: 1.24 to 1.90, P = .0001), while diabetes [Kolte 2018; Amat-Santos 2015; Olsen 2015; Bjursten 2019; Fauchier 2020; Tabata 2020; Butt 2019; Regueiro 2016] (RR 1.08, 95% CI: 0.86 to 1.35, P = .51), COPD [Kolte 2018;

Factors	Studies	Participants	Statistical Method	Pooled HR (95%Cl)	Р	<b> </b> <sup>2</sup>	Heterogeneity	Publication bias
Age	7	68302	IV, Random	0.97 (0.95, 0.99)	.007	<b>76</b> %	high	none
Male sex	8	68805	IV, Random	1.53 (1.24, 1.90)	.0001	57%	moderate	none
Diabetes	8	68805	IV, Random	1.08 (0.86, 1.35)	.51	50%	low	none
COPD	8	68805	IV, Random	1.03 (0.83, 1.28)	.8	4 <b>9</b> %	low	none
Chronic renal insufficiency	8	68805	IV, Random	0.95 (0.81, 1.11)	.49	<b>67</b> %	moderate	none
Aortic regurgitation (≥moderate)	4	29027	IV, Random	1.04 (0.89, 1.21)	.6	0%	insignificant	none
Self-expandable valve	4	20073	IV, Random	0.74 (0.58, 0.95)	.02	0%	insignificant	none
Transfemoral approach	6	51072	IV, Random	0.85 (0.71, 1.02)	.08	0%	insignificant	none
Orotracheal intubation	3	18625	IV, Random	1.65 (1.12, 2.43)	.01	60%	moderate	none
New pacemaker implantation	6	49888	IV, Random	1.46 (1.14, 1.87)	.003	0%	insignificant	none
Vascular injury	6	49888	IV, Random	1.20 (0.70, 2.06)	.51	54%	moderate	none
Residual aortic regurgitation ≥grade 2	4	19134	IV, Random	1.62 (1.01, 2.61)	.05	43%	low	none
Bleeding complication	4	37661	IV, Random	1.34 (0.75, 2.40)	.32	57%	moderate	none

Table 2. Test of Heterogeneity and Publication Bias for Each Outcome

Cl indicates confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; IV, inverse variance.

Amat-Santos 2015; Olsen 2015; Bjursten 2019; Fauchier 2020; Tabata 2020; Butt 2019; Regueiro 2016] (RR 1.03, 95% CI: 0.83 to 1.28, P = .80), chronic renal insufficiency [Kolte 2018; Amat-Santos 2015; Olsen 2015; Bjursten 2019; Fauchier 2020; Tabata 2020; Butt 2019; Regueiro 2016] (RR 0.95, 95% CI: 0.81 to 1.11, P = .49) and aortic regurgitation  $\geq$  moderate [Amat-Santos 2015; Olsen 2015; Bjursten 2019; Fauchier 2020] (RR 1.04, 95% CI: 0.89 to 1.21, P = .60) were not correlated with PVE after TVAR (Figure 2).

## **Procedure-Related Factors**

A self-expandable valve [Amat-Santos 2015; Bjursten 2019; Tabata 2020; Regueiro 2016] was associated with a lower risk of PVE after TVAR (RR 0.74, 95% CI: 0.58 to 0.95, P = .02) and orotracheal intubation [Amat-Santos 2015; Bjursten 2019; Regueiro 2016] was identified as a predictor of PVE after TVAR (RR 1.65, 95% CI: 1.12 to 2.43, P = .01), while transfemoral approach [Kolte 2018; Amat-Santos 2015; Olsen 2015; Bjursten 2019; Butt 2019; Regueiro 2016] was not correlated with PVE after TVAR approach (RR 0.85, 95% CI: 0.71 to 1.02, P = .08) (Figure 3).

# **Post-TAVI Characteristics**

Patients with a new pacemaker implantation [Kolte 2018; Amat-Santos 2015; Olsen 2015; Bjursten 2019; Tabata 2020; Regueiro 2016] (RR 1.46, 95% CI: 1.14 to 1.87, P =.003) and more than grade 2 residual aortic regurgitation [Amat-Santos 2015; Olsen 2015; Bjursten 2019; Regueiro 2016] (RR 1.62, 95% CI: 1.01 to 2.61, P = .05) after TAVR appeared to be more susceptible to PVE. Vascular injury [Kolte 2018; Amat-Santos 2015; Olsen 2015; Bjursten 2019; Tabata 2020; Regueiro 2016] (RR 1.2, 95% CI: 0.70 to 2.06, P = .51) and bleeding complications [Kolte 2018; Olsen 2015; Tabata 2020; Regueiro 2016] (RR 1.34, 95% CI: 0.75 to 2.4, P = .32) were not associated with PVE after TVAR (Figure 4). The results of each factor were summarized in Table 2. No significant publication biases were detected for each individual analysis.

# DISCUSSION

Transcatheter aortic valve replacement (TAVR) has emerged as an accepted alternative to surgical aortic valve replacement (SAVR). Its effect has been carefully evaluated in several RCT studies. The most recent PARTNER 3 study showed that TAVR was superior to SAVR in preventing death, stroke, and repeat hospitalization at one-year follow-up [Mack 2019]. Similarly, the EVOLUT Low Risk trial showed no difference in two-year outcomes (mortality, stroke) between SAVR and TAVR [Popma 2019]. Based on these new RCT trials, the indication for TAVR continues to shift toward patients at a younger age or lower risk [Thyregod 2015; Waksman 2018]. These patients will have a longer postoperative survival period in which may develop subsequent infective endocarditis on the prosthesis and require recurrent interventions. Although the incidence of PVE was proved to be rare in previous studies and the present metaanalysis (pooled incidence: 1.62%), the occurrence of TAVR-PVE is likely to become more frequent as implant numbers rise rapidly. Besides, we must keep in mind that the current diagnostic criteria for definite infective endocarditis such as Duke or modified Duke criteria are known to be less sensitive

in PVE [Kuttamperoor 2019]. That is why some guidelines recommended 18-fluorodeoxyglucose PET or singlephoton emission CT in the diagnosis of PVE to increase sensitivity. In addition, the incidence of para-valvular abscesses and fistulas emanating from the infected prosthetic valve is higher than PVE after SAVR [Ben-Shoshan 2016]. Moreover, TAVR-PVE can also lead to other complications include heart block, heart failure, renal failure, and septic shock and worsened mortality. On the other hand, the therapeutic methods for TAVR-PVE are quite limited. Consequently, the outcomes of TAVR-PVE are very unpromising. If prompt intervention is not undertaken, this severe complication in patients can ultimately prove fatal (pooled inhospital mortality: 22.3%) [Bax 2019; Tan 2015; Butt 2019]. Identification of predictors can facilitate targeted screening during follow-up and timely intervention, which has great value in clinical practice.

However, several studies based on single/multi-center data or different registries provide various and contradictory predisposing indicators for TAVR-PVE. The discrepancy may pose questionable advice to the clinical practice. To our best knowledge, this is the first meta-analysis aimed at identifying independent predictors of PVE in TAVR patients. 13 possible predisposing indicators were extracted from 8 trials, and according to currently available evidence, younger age, male sex, valve design, orotracheal intubation, pacemaker implantation, and residual moderate or severe regurgitation appeared correlated with the risk of subsequent endocarditis occurrence after TAVR. Although some highly speculative predisposing indicators, such as diabetes mellitus, COPD, access approach, or chronic renal dysfunction, have been identified as risk factors in some previous studies, they were proven to have no significant effects on the occurrence of TAVR-PVE in the present meta-analysis.

As shown in the present meta-analysis, the pool rate of PVE after TAVR was 1.83%; conversely the average incidence of PVE after SAVR was only 0.57% [Glaser 2017]. We speculate the remaining atheroma after TAVR plays an important role in the occurrence of TAVR-PVE. Additionally, the other reason may be the factor that biological prostheses are more reluctant to PVE compared with mechanical valves [Anantha-Narayanan 2020]. Finally, the present meta-analysis shows that the pooled postoperative 30-day mortality was 22%; it seems that SAVR-PVE has a lower postoperative 30-day mortality (13%) than TAVR-PVE [Manne 2012].

Some nonprocedural risk factors such as age and sex were related to the development of PVE after TAVR. Younger patients are more likely to develop PVE after TAVR, while male patients had 1.5 times higher risk for the development of prosthesis infection. Some researchers suggested that younger patients that have undergone TAVI commonly have a higher comorbidity burden, which might correlate with susceptibility to infections of the prosthesis [Tabata 2020; Regev 2017]. One possible explanation for the differences in sex is the female protective theory based on the endothelial protection effect of estrogen. Nevertheless, further fundamental studies are required to reveal the underlying mechanisms. Age and sex are two risk factors one cannot modify, but there are other modifiable factors associated with the development of TAVR-PVE. Self-expandable valve (SEV) was less prone to have endocarditis compared with balloon-expandable valve (BEV). The differences between these two systems in terms of the design, loading processing of prosthetic valve, and delivery system and procedure may help explain this phenomenon [Regueiro 2019; Abdel-Wahab 2016]. The mechanism could be related to the different delivery techniques as BEV implantation could cause greater tissue damage secondary to balloon dilatation during prosthetic valve deployment. It is worth mentioning that in the study of Amat-Santos et al [Amat-Santos 2015], the authors identified SEV as an independent risk factor for PVE after TAVR by univariate analysis (HR, 4.56; 95% Cl, 2.34-10.3; P = .025). However, according to the supplemental material, there were 3067 patients enrolled, and 29 patients were diagnosed with PVE. Among these 29 patients with IE, 16 patients (55.2%) received a SEV, while in 3028 patients without PVE, 2229 patients (73.6%) received a SEV. The calculated HR for PVE with SEV in the univariate analysis should be 0.45 with 95% CI 0.218-0.933 (P = .032), which leads to just the opposite of the conclusion of the paper. So we only adopted the primary data from this paper for meta-analysis. Orotracheal intubation is another predictor for TAVR-PVE. Orotracheal intubation indicated general anesthesia, mechanical ventilation, and more complicated and invasive procedures that may increase bacteremia and subsequent prosthesis contamination. TAVR procedure often requires a temporary pacemaker insertion. In addition, due to the pressure of an expandable stent on left ventricle outflow tract, TAVR patients had a higher incidence of heart block compared to SAVR [Young Lee 2015] and required a permanent pacemaker be implanted. Pacemakers have been shown to be a nidus for infection and might lead to the development of PVE. The crude delivery of the device is another potential avenue for infection. Residual moderate or severe aortic regurgitation is related to prosthesis-annulus size mismatch, technical difficult procedures with prosthesis malpositioning, and is more common when treating heavily and asymmetrically calcified aortic valves. Residual aortic regurgitation may predispose to developing endocarditis because of the high-velocity regurgitate jet damages or otherwise increase in the vulnerability of endothelial surfaces [Athappan 2013]. The pockets between the prosthesis and native valve allow for thrombus formation, which then can serve as a nidus for infection [Kuttamperoor 2019].

# Study Limitations

Several limitations to the current meta-analysis need to be acknowledged. The main limitation is the design of included studies because both retrospective and prospective observational studies are exposed to several biases. Although we performed a thorough assessment of their methodological quality, the risk of bias being inherent to the study design cannot be ruled out completely. The use of different generation transcatheter prostheses from various manufacturers in these studies may also limit the validity of the findings in the present meta-analysis, since there are certain, albeit minor, differences in different prostheses. Finally, the data analyzed in this study are all observational with no randomized trials, leading to an indication bias. However, in the shortage of randomized data, the findings of our meta-analysis can further advise the practice of TAVR clinicians and influence future studies.

# Conclusion

Despite being infrequent, PVE after TAVR is a deadly complication associated with high rates of mortality. Several clinical characteristics, such as age, male sex, valve design, orotracheal intubation, pacemaker implantation, and residual regurgitation, show adequate specificity for the occurrence of TAVR-PVE. This finding raises a flag of warning that surgeons and physicians should perform TAVR with particular attention of PVE in the specific patient cohort. As TAVR indications continue to expand to lower risk and younger patients, consensus guidelines should clarify the appropriate diagnosis and management of PVE after TAVR.

## REFERENCES

Abdel-Wahab M, Neumann FJ, Mehilli J, et al. 2015. 1-year outcomes after transcatheter aortic valve replacement with balloon-expandable versus self-expandable valves: Results from the choice randomized clinical trial. J Am Coll Cardiol 66:791-800.

Amat-Santos IJ, Messika-Zeitoun D, Eltchaninoff H, et al. 2015. Infective endocarditis after transcatheter aortic valve implantation: Results from a large multicenter registry. Circulation 131:1566-74.

Anantha-Narayanan M, Reddy YNV, Sundaram V, et al. 2020. Endocarditis risk with bioprosthetic and mechanical valves: Systematic review and meta-analysis. Heart 106:1413-19.

Athappan G, Patvardhan E, Tuzcu EM, et al. 2013. Incidence, predictors, and outcomes of aortic regurgitation after transcatheter aortic valve replacement: Meta-analysis and systematic review of literature. J Am Coll Cardiol 61:1585-95.

Bax JJ, Delgado V. 2019. Prosthetic valve endocarditis after surgical and transcatheter aortic valve replacement: Infrequent, but poor outcome. Euro Intervention 15:e484-5.

Ben-Shoshan J, Amit S, Finkelstein A. 2016. Transcatheter aortic valve implantation infective endocarditis: Current data and implications on prophylaxis and management. Curr Pharm Des 22:1959-64.

Bjursten H, Rasmussen M, Nozohoor S, et al. 2019. Infective endocarditis after transcatheter aortic valve implantation: A nationwide study. Eur Heart J 40:3263-9.

Braghiroli J, Kapoor K, Thielhelm TP, Ferreira T, Cohen MG. 2020. Transcatheter aortic valve replacement in low risk patients: A review of partner 3 and EVOLUT low risk trials. Cardiovasc Diagn Ther 10:59-71.

Butt JH, Ihlemann N, De Backer O, et al. 2019. Long-term risk of infective endocarditis after transcatheter aortic valve replacement. J Am Coll Cardiol 73:1646-55.

Fauchier L, Bisson A, Herbert J, et al. 2020. Incidence and outcomes of infective endocarditis after transcatheter aortic valve implantation versus surgical aortic valve replacement. Clin Microbiol Infect 26:1368-74.

Glaser N, Jackson V, Holzmann MJ, Franco-Cereceda A, Sartipy U. 2017. Prosthetic valve endocarditis after surgical aortic valve replacement.

Circulation 136:329-31.

Higgins JP, Thompson SG. 2002. Quantifying heterogeneity in a metaanalysis. Stat Med 21:1539-58.

Kolte D, Goldsweig A, Kennedy KF, et al. 2018. Comparison of incidence, predictors, and outcomes of early infective endocarditis after transcatheter aortic valve implantation versus surgical aortic valve replacement in the united states. Am J Cardiol 122:2112-9.

Kuttamperoor F, Yandrapalli S, Siddhamsetti S, Frishman WH, Tang GHL. 2019. Infectious endocarditis after transcatheter aortic valve replacement: Epidemiology and outcomes. Cardiol Rev 27:236-41.

Liberati A, Altman DG, Tetzlaff J, et al. 2009. The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 339:b2700.

Mack MJ, Leon MB, Thourani VH, et al. 2019. Transcatheter aorticvalve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 380:1695-705.

Manne MB, Shrestha NK, Lytle BW, et al. 2012. Outcomes after surgical treatment of native and prosthetic valve infective endocarditis. Ann Thorac Surg 93:489-93.

Misawa Y. 2015. Valve-related complications after mechanical heart valve implantation. Surg Today 45:1205-9.

Olsen NT, De Backer O, Thyregod HG, et al. 2015. Prosthetic valve endocarditis after transcatheter aortic valve implantation. Circ Cardiovasc Interv 8:e001939.

Popma JJ, Deeb GM, Yakubov SJ, et al. 2019. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 380:1706-15.

Regev E, Finkelstein A, Assali A, et al. 2017. Comparison of outcome of transcatheter aortic valve implantation for severe aortic stenosis in 3 age groups (</=70; 71 to 80, and >/=81 years). Am J Cardiol 120:1607-11.

Regueiro A, Linke A, Latib A, et al. 2016. Association between transcatheter aortic valve replacement and subsequent infective endocarditis and in-hospital death. JAMA 316:1083-92.

Regueiro A, Linke A, Latib A, et al. 2019. Infective endocarditis following transcatheter aortic valve replacement: Comparison of balloonversus self-expandable valves. Circ Cardiovasc Interv 12:e007938.

Tabata N, Al-Kassou B, Sugiura A, et al. 2020. Predictive factors and long-term prognosis of transcatheter aortic valve implantation-associated endocarditis. Clin Res Cardiol 109:1165-76.

Tan HL, Chai LY, Yeo TC, Chia BL, Tambyah PA, Poh KK. 2015. Predictors of in-hospital adverse events in patients with prosthetic valve infective endocarditis. Heart Lung Circ 24:705-9.

Thyregod HG, Steinbruchel DA, Ihlemann N, et al. 2015. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the all-comers notion randomized clinical trial. J Am Coll Cardiol 65:2184-94.

Waksman R, Rogers T, Torguson R, et al. 2018. Transcatheter aortic valve replacement in low-risk patients with symptomatic severe aortic stenosis. J Am Coll Cardiol 72:2095-105.

Young Lee M, Chilakamarri Yeshwant S, Chava S, Lustgarten LD. 2015. Mechanisms of heart block after transcatheter aortic valve replacement - cardiac anatomy, clinical predictors and mechanical factors that contribute to permanent pacemaker implantation. Arrhythm Electrophysiol Rev 4:81-5.